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BETA-PROPIOLACTONE FOR THE STERILIZATION OF
BIOLOGICAL MATERIALS
GERALD A . LOGRIPPO, M . D . ''

INTRODUCTION
Although the sterilization of biological materials has been widely used for many
years, the agents employed are still not entirely satisfactory. Moreover, the scope of
biological materials which can be sterilized has been limited. Heat, ultraviolet irradiation, formalin and phenol have been the most commonly used agents for sterilization.
However, with these agents there is a rather marked alteration of protein material
with the loss of the biological characteristics necessary for clinical usefulness. In
addition, in recent years the problem of virus contamination has been brought to the
attention of the clinicians more forcibly than ever before. This has been further
complicated by the fact that the bactericidal agents in common use destory the biological
material before they effectively inactivate the viruses. This has been true in the
sterilization of plasma where there has been no satisfactory means of destroying the
hepatitis virus, an increasing hazard in the use of transfusions.'-^ More recently
Beutler and Dern^ have demonstrated another virus agent that is transmitted from
the blood of healthy donors to recipients.
It is known that at least 16 viruses, infectious to man, can produce a viremic
phase. How many of these agents persist in the "carrier stage" in man is difficult to
prove with our present laboratory technics. Although the technics are not sensitive
enough to detect the trace quantities that may persist, these trace quantities are sufficient
to transmit the disease to susceptible human hosts whenever blood, blood products or
homologous tissue are used in man. With the increasing use of biological materials of
human origin being used in man, sterilization of these products must be insured not
only from the bacterial agents but also from all of the microbiological pathogens.
Beta-propiolactone (BPL) has been reported from this laboratory as a more
satisfactory sterilizing agenf*'''''''"-' against viruses, bacteria, fungi, spore forms of
bacteria and fungi and mahgnant cells. Moreover, sterilization can be obtained at
drug concentrations which are not deleterious to tissue proteins. BPL has been successfully developed and employed in several different clinical problems involving the use
of biological materials. These are (1) the sterilization of human plasma, (2) the
estabhshment and operation of a human tissue bank and (3) the preparation of inactivated virus vaccines.
BETA-PROPIOLACTONE
The chemical agent, beta-propiolactone (BPL) CH2CH2C = O, is a colorless stable
1— O —I
liquid in its concentrated state but is unstable in aqueous solutions. It can be
satisfactorily stored in plastic containers or in neutraglass sealed ampules at -20 to -30
degrees centigrade. BPL has a specific gravity of 1.149 and is 37.5% (by volume)
"•Division of Microbiology, Department of Laboratories, Henry Ford Hospital.
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soluble in water at 25° C. It reacts readily with hydroxyl, amino, carboxyl sulfhydryl
and phenolic groups,'"-"-'^ all of which are associated with proteins.
The instability of the chemical structure of beta-propiolactone accounts for its
unavailability in the past. Although the agent was known to exist in 1885, it was not
until 1915 that Johannson" actually prepared the agent. In 1941, Kung"" found a
practical method for the manufacture of beta-propiolactone.
After sitting on the
shelves of the organic chemists for nine years with no practical use for the compound,
it was tested for its virucidal action in plasma during a routine screening program
conducted in this laboratory. The recent synthesis of the lactone form made possible
an extensive study of reactions of the drug with biological materials for sterilization of
plasma, tissues and the preparation of inactivated virus vaccines.
STERILIZATION OF H U M A N PLASMA
Previous publications give in more detail the superiority of BPL over nitrogen
mustard, sulfur mustard, ethylene oxide, photodynamic action of dyes and ultraviolet
irradiation for the inacfivation of numerous viruses artificially seeded in plasma and
those naturally occurring in plasma during the stage of viremia.^-' Extensive studies
from this laboratory also show that a wide margin of safety exists between the virucidal
concentrations" of beta-propiolactone and the toxicity concentrations"-" of beta-propiolactone. However, since the hepatitis virus is not an agent which can be yet studied
in the experimental laboratory, the effectiveness of beta-propiolactone upon this agent
remains to be answered in human volunteers. Although plasma treated with 0.6% betapropiolactone concentration is not toxic to man upon intravenous administration, this
concentration is 1.5 times that necessary to inactivate the most resistant laboratory virus
(eastern equine encephalomyelitis) and 12 times that necessary to inactivate the most
sensitive virus (lymphocytic choriomeningitis) when these agents are seeded in plasma.
However, in order to maintain the integrity of the fibrinogen in plasma, a concentration
of 0.45% beta-propiolactone should not be exceeded. Since this concentration is only
slightly in excess of that necessary to inactivate the most sturdy laboratory viruses, it
may not be sufficient to inactivate the trace quantities of hepatitis virus that may be
theoretically present. For these reasons, the combination of beta-propiolactone and
ultraviolet irradiation previously reported' was more extensively studied.'8,19,20,21,22
Animal experimentations with the eastern equine encephalomyelitis virus (EEE)
clearly show that there is always an additive and often a synergistic virucidal effect
with beta-propiolactone and ultraviolet irradiation.* The same degree of virus inacfivation (i.e., nondetectable quantities) can be obtained in combination with 1/3 to
1/4 the beta-propiolactone concentration and 1/3 to 1/4 the ultraviolet irradiation
than when either agent is used alone. What is more important is the fact that the
combination can be used in marked excess of that necessary for sterilization and still
maintain the integrity of the fibrinogen and other plasma proteins as demonstrated
by electrophoretic patterns. With a wider range between sterilization dosage and protein
alteration, the combination here shown stands a greater chance of inactivating the
hepatitis virus in human plasma.
Plasma treated with 0.35% beta-propiolactone and ultra.violet irradiation intensity
recommended and used by the National Institute of Health Standards produces a
*(The Dill ultraviolet apparatus was used for these studies).
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product which is clear and amber in appearance, stores well at refrigerator temperature,
and is well tolerated by patients. Over 100 units have been administered to infants and
adults without any clinical pathological manifestations.
ESTABLISHMENT A N D OPERATION OF A H U M A N TISSUE BANK
With the ever increasing demand for sterile tissue transplants in the field of
surgery and with human autopsy material being the most likely source for an adequate
supply of homotransplants, a simple, inexpensive and safe procedure for sterilizing
tissue is greatly needed. The usual practice of testing for bacterial and mycotic contamination overlooks the potential hazards of virus infection, malignant growths and
parasites. It is possible with the use of beta-propiolactone to completely sterilize tissue
supplied from autopsy material and thus establish a human tissue bank. Such a bank
has been in operation at the Henry Ford Hospital for three and one-half years.
The human arterial bank was first established in October 1953, having been
preceded by study of arterial transplants in dogs." These experiments were initiated
by Dr. C. Lam and associates in Surgery with the cooperation of the Department of
Laboratories.'-' After two years work, the results in dogs were concluded to be highly
satisfactory, and it was felt that trial of homologous grafts in man was justified. The
clinical trial was carried out by Dr. D. E. Szilagyi24,25,26,27 and associates in the Department of Surgery with the cooperation of the Department of Laboratories.
The tissue bank operates in the following manner:
1. A special permit for the procurement of human arteries is necessary. This
is easiest to obtain from the family at the time the autopsy permit is being
signed. In obtaining the arteries, no exceptions are made regarding age and
cause of death.
2. A surgical resident is charged with the responsibilities of obtaining, preparing,
discarding poor segments, classifying and recording data pertaining to the
arteries.
3. The arteries are obtained without aseptic precautions and sterilized within 24-36
hours from time of death, without elaborate procedures or inconvenience to
any one concerned.
4. The sterilization and completion of the sterility tests are the responsibility of
a bacteriology technician. The tissues are then returned to the respective
surgical services for storage.
Two-hundred and sixty-eight operations have been performed with beta-propiolactone sterilized arteries by the Department of Arterial Surgery. In no case was there
evidence of failure being due to inadequate sterilization, nor has there been any evidence
of infection, either bacterial or viral. After successful sterilization of arteries and
acceptance by the host, sterilization studies were extended to bone tissue with the
cooperation of Dr. C. L. Mitchell and Dr. J. Fleming, Department of Orthopedic
Surgery.
The bone bank was established in July 1955, again placing a resident in Orthopedic
Surgery in charge of the preparation of the bone segments in the sizes and shapes
desired by the surgeons. Usually ribs, iliac crest and vertebral bodies afford an ample
supply of cancellous and cortical bone without special permits. To sterilize bone it
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is important to remember that segments can be as long and as wide as the surgeon
wishes, but they cannot be greater than 6 mm. thick. This maximum thickness was
determined by experimental data obtained with bone pieces varying in thickness from
1-2-3-6-9 and 12 mm. sizes. These were contaminated in bacterial broth suspensions
for 18 hours before sterilizing with the beta-propiolactone. In addition, varying thicknesses obtained from infected rabbits and guinea pigs during the stage of bacteremia
and viremia were sterilized.' A l l specimens were consistently sterilized at 6 mm.
thickness. Sterilization at 9 mm. thickness is inconsistent.
After sterilization the bone can be kept frozen at —20 to —30° C. in an
ordinary deep freeze unit, or lyophilized (freeze-dried) and stored at room temperature
in vacuum. The clinical results of beta-propiolactone sterilized bone have been very
satisfactory.
As of March 1, 1957 specimens from the BPL treated bone bank have been used
in 70 operations. The procedures have included filling of large cysts, spinal fusions
for tuberculosis and scoliosis, grafting of fractures both fresh and old, and for various
other fusions. Only one infection was noted in this series (open reduction of os calcis
fracture with skin slough and infection on the 13th postoperative day). However,
this case healed without losing the graft or the reduction.
More recently sterilized skin and cartilage have also been used with the cooperation
of Dr. R. H . Clifford and Dr. W. D. Butt, Department of Plastic Surgery. However,
this is still in the early trial stage. Sufficient evidence has been collected to say that
beta-propiolactone sterilized, homologous, skin grafts are as serviceable as the nontreated, homologous, skin grafts, without the complication of infection. The rejection
period is the same as that of the nontreated, homologous, skin grafts.
The results with cartilage, again few in number, indicate that sterilization is
satisfactory. The cartilage transplants occasionally resorb as do fresh autogenous transplants or nonsterilized, refrigsrated, homologous transplants. When resorption takes
place the reaction is slow with no evidence of toxic or inflammatory reactions.
In conclusion, it can be stated that, with the use of beta-propiolactone as the
sterilizing agent, a tissue bank can be established in a hospital of any size with a
minimum of equipment and no need for highly skilled technical assistance. At the
present time, establishment and operation of a tissue bank is most useful for the preparation and storage of sterile, homologous, arterial, bone, cartila.ge and skin transplants.
ANTIGENICITY OF BETA-PROPIOLACTONE
INACTIVATED-VIRUS VACCINES
In the preparation of inactivated virus vaccines, the margin of safety between
complete virus inacfivation and the degree of antigenicity retained is so narrow that
a search for a more satisfactory agent has not abated.
In previous reports^'-" and in studies in progress, beta-propiolactone seems superior
to other chemical agents for the preparation of inactivated virus vaccines. I t inactivates viruses completely and irreversibly in 10-15 minutes at 37° C. whereas
formalin and phenol require days under the same conditions. The beta-propiolactone concentration can be added in excess of the minimal effective virucidal concentration with
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a wide margin of safety between the complete inacfivation of viruses and loss of antigenicity. Moreover, significantly higher degrees of antigenicity have been obtained
with beta-propiolactone inactivafed-virus vaccines than with phenol — or formalin —
inactivated vaccines under parallel conditions. The vaccine preparations were made
with rabies, eastern equine encephalomyelitis, murine (MM-strain) encephalomyocarditis
and poliomyelitis viruses.
Upon demonstration by animal experimentation of the superiority of beta-propiolactone inactivated virus vaccines, human trials with such preparations have begun.
Peck, Powell and Culbertson,^''-^' from the Lilly Laboratories for Clinical Research,
Indianapolis General Hospital and the Lilly Research Laboratories, have recently
prepared and clinically tested a beta-propiolactone killed rabies vaccine with good
results in man. The rabies vaccine was prepared from embryonated duck eggs in place
of the conventional rabbit brain material. The absence of brain tissue in this preparation and the appearance of detectable antibodies between 7 and 10 days after the first
inoculation indicate marked improvement in the methods of immunization against rabies.
SUMMARY
Beta-propiolactone, a new chemical agent, has been demonstrated to be a useful
substance in the sterilization of biological materials. Its unique properties, not available
in other agents used for treating biological material, have made possible the treatment
of human plasma for the inacfivation of viruses, without destroying the usefulness of
the product for clinical use. Beta-propiolactone has made possible the establishment
of an inexpensive and practical tissue bank by successful sterilization of contaminated
tissue from autopsy material without destroying the properties of the transplants for
clinical use. In addition, beta-propiolactone is finding its place in the preparation of
safer and more potent inactivated virus vaccines.
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